TLR8/NF-κB Reporter – HEK293 Recombinant Cell Line
TLR8/NF-κB Luciferase Reporter HEK293 Cell Line is a HEK293 cell line expressing firefly luciferase under the control of NF-κB response elements with constitutive expression of human TLR8 (Toll-like receptor 8) (GenBank Accession No. NM_138636), a member of the toll-like receptor (TLR) family.
This cell line has been validated with C1097, Motolimod, Afimetoran and Enpatoran.
Interested in screening and profiling inhibitors, blocking antibodies, or activators of TLR8 without the need to purchase and license the cell line? Check out our Cell Signaling Pathway Screening.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Media Required for Cell Culture
| Name | Ordering Information |
| Thaw Medium 1 | BPS Bioscience #60187 |
| Growth Medium 1W | BPS Bioscience #78854 |
Materials Required for Cellular Assay
| Name | Ordering Information |
| CL097 (imidazoquinoline compound) | Invivogen #tlr1-c97 |
| Motolimod | MedChemExpress #HY-13773 |
| Afimetoran | MedChemExpress #HY-139567 |
| Enpatoran hydrochloride | MedChemExpress #HY-134581A |
| 96-well tissue culture treated white clear-bottom assay plate | Corning #3610 |
| ONE-Step™ Luciferase Assay System | BPS Bioscience #60690 |
| Luminometer |
The cell line has been screened to confirm the absence of Mycoplasma species.
The family of Toll-like receptors (TLRs) acts as primary sensors that detect a wide variety of microbial components and elicit innate immune responses. TLR8 (toll-like receptor 8), also known as CD288 (cluster of differentiation 288), is expressed mainly in the lung and leukocytes. TLR8 is an endosomal receptor that recognizes single stranded RNA (ssRNA) that is GU-rich. TLR8 is involved in the recognition of ssRNA viruses such as Influenza, where TLR8 binding to the viral RNA recruits MyD88 and leads to activation of the transcription factor NF-κB and an antiviral response. TLR8 has also been linked to cancer, leading to production of inflammatory proteins in dendritic cells. TLR8 agonists such as motolimob have been used as adjuvant therapies in cancer therapy, with the aim of stimulating the immune system. Further studies into the molecular pathways involving TLR8 and the development of new agonists may open new avenues for the treatment of TLR8-related diseases.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.